Biotech | January 24, 2022
USFDA approves IND application for Allied’s cancer treatment
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward
Previously, the use of the drug was limited to patients requiring hospitalization
Go-ahead for pivotal clinical trial which is expected to commence by March
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
First launches expected in H1 2022
It is the first monoclonal antibody drug for use in any animal species
This surpasses the number of approvals supported in 2020
Novavax' vaccine has received authorizations of the vaccine in over 170 countries
Earlier last week the U.S. FDA had also shortened the time to receive a Pfizer booster shot from six months to five months for everyone 12 and older
Subscribe To Our Newsletter & Stay Updated
